Bottom line
FTXH vs LOGSX: the short answer
FTXH (First Trust Nasdaq Pharmaceuticals ETF) and LOGSX (Live Oak Health Sciences Fund) share a meaningful slice of their top holdings — about 41% by weight.
FTXH is cheaper at 0.6% vs 1.04% — a difference of $44 a year per $10,000 invested.
Over five years, LOGSX returned +8.1% a year vs +6.5% for FTXH.
Updated Nov 19, 2026
FTXH vs LOGSX side by side
| FTXH | LOGSX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | First Trust | Oak Associates |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.6% | 1.04% |
| Annual cost per $10k | $60 | $104 |
| 10-yr cost on $10k (prospectus) | — | $1,271 |
| Max front load | None | — |
| 12b-1 fee | 0% | — |
| 1-yr return | +24.0% | +19.6% |
| 5-yr return (annualized) | +6.5% | +8.1% |
| 10-yr return (annualized) | — | +7.3% |
| Best quarter | +18.3% | +13.4% |
| Worst quarter | −17.4% | −13.1% |
| Net assets (fund) | $36.2M | $56.1M |
| Number of holdings | 51 | 28 |
| Portfolio turnover | 35% | 24% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FTXH | LOGSX | Difference |
|---|---|---|---|
| 2025 | +24.0% | +19.6% | +4.4% |
| 2024 | +3.0% | +0.2% | +2.8% |
| 2023 | −1.4% | +1.2% | −2.6% |
| 2022 | +2.5% | +3.7% | −1.2% |
| 2021 | +6.1% | +17.5% | −11.4% |
| 2020 | +10.9% | +6.0% | +4.9% |
| 2019 | +22.4% | +19.0% | +3.4% |
| 2018 | −8.4% | −4.0% | −4.4% |
| 2017 | +18.8% | +13.4% | +5.4% |
Source: Fund prospectus bar charts
Holdings overlap
13 of FTXH's top 25 holdings also appear in LOGSX's top 25.
| Holding | FTXH | LOGSX |
|---|---|---|
| Eli Lilly & Company | 7.77% | 1.99% |
| Merck & Company Inc | 7.07% | 3.16% |
| Johnson & Johnson | 6.96% | 3.77% |
| Bristol-myers Squibb Company | 6.29% | 4.02% |
| Cardinal Health Inc | 3.53% | 5.86% |
| Vertex Pharmaceuticals Inc | 3.41% | 3.26% |
| Amgen Inc | 3.18% | 4.86% |
| Gilead Sciences Inc | 2.89% | 3.50% |
| United Therapeutics Corp | 2.72% | 5.11% |
| Regeneron Pharmaceuticals Inc | 2.72% | 4.43% |
| Incyte Corp | 2.39% | 3.30% |
| Exelixis Inc | 1.72% | 4.95% |
| Medpace Holdings Inc | 1.41% | 3.69% |
Source: SEC Form N-PORT
FTXH top 10
- Eli Lilly & Company — 7.77%
- Abbvie Inc — 7.39%
- Merck & Company Inc — 7.07%
- Johnson & Johnson — 6.96%
- Bristol-myers Squibb Company — 6.29%
- Biogen Inc — 3.84%
- Viatris Inc — 3.62%
- Cardinal Health Inc — 3.53%
- Vertex Pharmaceuticals Inc — 3.41%
- Amgen Inc — 3.18%
LOGSX top 10
- N/a — 6.91%
- Cardinal Health Inc — 5.86%
- Jazz Pharmaceuticals Plc — 5.77%
- United Therapeutics Corp — 5.11%
- Exelixis Inc — 4.95%
- Amgen Inc — 4.86%
- Lantheus Holdings Inc — 4.68%
- Novartis Ag — 4.67%
- Mckesson Corp — 4.53%
- Cencora Inc — 4.46%
FAQ
What is the difference between FTXH and LOGSX?
Which is cheaper, FTXH or LOGSX?
Should I own both FTXH and LOGSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.